CTOs on the Move

Marinus Pharmaceuticals

www.marinuspharma.com

 
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.marinuspharma.com
  • 5 Radnor Corporate Center 100 Matsonford Road Suite 500
    Radnor, PA USA 19087
  • Phone: 484.801.4670

Executives

Name Title Contact Details

Funding

Marinus Pharmaceuticals raised $70M on 12/13/2019

Similar Companies

Optinose

We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). In September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18 years of age or older. XHANCE was made widely available through commercial channels in April 2018. We have initiated two Phase 3b clinical trials of XHANCE for a follow-on indication for the treatment of chronic sinusitis and expect top-line results by the end of 2021 from one trial and in the first half of 2022 from the second trial. If successful, we believe XHANCE would be the first drug therapy product approved by the FDA for the treatment of chronic sinusitis. As of February 28, 2021, we had a total of 204 full-time employees and three part-time employees. A majority of our employees are field-based, in customer-facing roles. Culture is a critical element in the management of our organization. Our talented employees, known as colleagues, are focused on driving our business with the Optinose values as the foundation for all our efforts. Our goal is that each colleague feels a deep connection to what they do, loves coming to work and is aligned to our One Mission – to improve lives. Our values of Authenticity, Fearless Conversations, Friendship, Openness, Perseverance and Possibility Thinking guide our actions and decisions.

Strativa Pharmaceuticals

Strativa Pharmaceuticals is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Vetagro

Vetagro is a company that specializes in feed additive development and production for the animal feed industry. They focus on developing targeted solutions through scientific research, technological development, innovative formulation, and a focus on q...

DK Sinopharma

DK Sinopharma is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Infinant Health

Infinant Health is a life sciences company that is committed to changing the trajectory of human health, one baby at a time, through their deep understanding of infant nutrition and the gut microbiome.